In this encouraging scenario, this review aims at discussing B7-H3 as a possible therapeutic target in pediatric tumors, solid or hemopoietic, other than the prototypical NB, providing an updated and comprehensive overview of preclinical results and ongoing clinical trials (Table 1). The gene discussed is CD276; the disease is neuroblastoma.